Drug intelligence / Profile preview

Pep-98-NSC74859 conjugate

Development stage
Preclinical
Lead developer
Seoul National University
Modality
Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
01

Overview

Pep-98-NSC74859 conjugate is a peptide-drug conjugate consisting of Pep-98, a cell-penetrating peptide (CPP) derived from the reverse-transcriptase subunit of human telomerase (hTERT), conjugated to NSC74859 (also known as S3I-201), a selective inhibitor of signal transducer and activator of transcription 3 (STAT3). Developed by researchers at Seoul National University, the conjugate is designed to selectively target and deliver the STAT3 inhibitor into cancer cells, particularly head and neck cancer cells, while sparing normal cells. By utilizing the cancer-specific cell-penetrating activity of Pep-98, the conjugate significantly enhances the intracellular delivery and anti-cancer efficacy of NSC74859, allowing for a substantial reduction in the required therapeutic dose and minimizing non-specific toxic side effects.

Other names
NSC 74859-pep98NSC74859-pep98NSC-74859-pep98NSC 74859-pep98 conjugateNSC74859-pep98 conjugateNSC-74859-pep98 conjugatePep 98-NSC74859Pep98-NSC74859Pep-98-NSC74859Pep 98-NSC74859 conjugatePep98-NSC74859 conjugatePep-98-NSC74859 conjugatePep 98-NSC74859 conjugatesPep98-NSC74859 conjugatesPep-98-NSC74859 conjugates

Beyond the preview

Go deeper on Pep-98-NSC74859 conjugate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pep-98-NSC74859 conjugate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call